


MDM2-recruiting PROTAC Offers Superior, Synergistic Anti-proliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53

John Hines¹, Schan Lartigue¹, Hanqing Dong², Yimin Qian² and Craig M. Crews^{1,3,4}

¹Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut 06520; ²Arvinas, LLC, New Haven, Connecticut 06511; ³Department of Chemistry, Yale University, New Haven, Connecticut 06520; ⁴Department of Pharmacology, Yale University, New Haven, Connecticut 06520

Supplementary Data File – Fig. S1



Supplementary Figure S1: Comparison of PROTAC activity to that of combination treatment. Cell viability assay of HCT1116 cells treated with increasing concentrations of either the PROTAC A1874 or a combination of its component ligands (JQ1 and idasanutlin) in equimolar amounts.